Patent Yard Sign in
Canadian application, no grantCanada

3-benzoylindole derivatives and drugs containing the same

CA 2294772 A1 · Owner: Nagano, Eiichi · Inventors: Sato, Hiroki; Fukuda, Yoichi; Nagano, Eiichi

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

3-Benzoylindole derivatives represented by general formula (I) wherein R1 represents lower alkyl; n is an integer of from 1 to 5; R2 and R3 represent each hydrogen, lower alkyl or optionally substituted phenyl; and R4 represents hydrogen or lower alkyl. Because of having a potent .alpha.1-adrenergic receptor blocking effect and a testosterone 5.alpha.-reductase inhibitory effect and showing a high safety, these compounds are useful as preventives and/or remedies for prostatic hypertrophy urinary disorders in association , with prostatic hypertrophy baldness or acne.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed July 15, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 15, 2018.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 15, 2020.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJuly 15, 1998
GrantedNo grant recorded
Term endedJuly 15, 2018
Patent numberCA 2294772 A1
Classification (IPC)C07D209/12 +1 more

Timeline

Timeline From CIPO dates

1999200120032005200720092011201320152017Application filedJuly 15, 1998Term endedJuly 15, 2018

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.